article thumbnail

Cloud robotics labs are accelerating drug discovery and development

Pharmaceutical Technology

Drug discovery and development is an incredibly expensive and time-consuming process, taking between 12 and 18 years, and costing on average between $2 billion and $3 billion. This helps to reduce human error and provide more reliable, replicable results and increase the speed of drug discovery and development processes.

article thumbnail

Leading Autoimmune Diseases to Undergo Robust Improvement in Treatment by Major Pharma Companies

Delveinsight

However, some of the key pharma companies at the global level have shifted their focus towards these diverse diseases. Through this article, we have covered the major autoimmune diseases and the key companies striving to transform the treatment landscape of the respective disease.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

UK Vaccine Taskforce head lifts lid on Novavax deal

pharmaphorum

The UK’s unique offering as a life sciences research hub helped convince US biotech Novavax to develop its COVID-19 jab there, according to the head of the country’s Vaccines Taskforce. . If you look at the development, we signed 15,000 people in six weeks in a trial set up by the NHS.

article thumbnail

GSK opens £10m AI hub in London

pharmaphorum

The area is being reimagined as a life sciences and technology hub and is already home to the Francis Crick Institute biomedical research organisation. With AI the pharma industry hopes to reduce the number of drugs that fail during the clinical development process, a huge financial drain on the industry.

article thumbnail

Initiative to measure carbon impact of clinical trials

Drug Discovery World

The CoI currently has 25 members from Japan, US, and Europe, including top 10 pharma companies, CROs, and academic representatives. Growing pressure on life sciences. To prepare for this change, the Alliance believes that companies working together on assessing the impact of trials is a key starting point.

article thumbnail

Deep Dive: Oncology 2022

pharmaphorum

Eradicating cancer is an ambitious goal for oncologists and life science companies around the world. As this issue’s contributors discuss, by working together pharma companies and healthcare providers can significantly enhance oncology treatment for patients.

article thumbnail

HEOR and Market Access Strategies in Today’s Drug Development Landscape – Insights from AstraZeneca’s Dr. Heather McDonald

XTalks

In the specialized, personalized and advanced medicines spaces, this work should start very early — as early as Phase I or Phase II of clinical development. In the specialized, personalized and advanced medicines spaces, this work should start very early — as early as Phase I or Phase II of clinical development.

Marketing 105